Related Experiment Videos
[Urapidil: hypotension induced in neuroanesthesia]
M Scafuro1, G Cafaggi, F Petrella
1Istituto di Anestesia e Rianimazione, Università degli Studi di Napoli.
Minerva Anestesiologica
|April 1, 1992
Summary
Urapidil effectively lowered mean arterial pressure (MAP) by approximately 25% in 31 patients undergoing neurosurgery. This antihypertensive medication demonstrated safety without impacting cardiac frequency during inductive and preoperative phases.
Area of Science:
- Anesthesiology
- Pharmacology
- Neurosurgery
Context:
- Management of blood pressure is critical during neurosurgical procedures.
- Intraoperative hypertension poses risks, including increased bleeding and neurological damage.
- Urapidil is an antihypertensive agent with alpha-blocking and beta-blocking properties.
Purpose:
- To evaluate the efficacy and safety of urapidil for blood pressure control in patients undergoing neurosurgery.
- To assess the impact of urapidil on mean arterial pressure (MAP) and cardiac frequency.
- To determine optimal dosing for urapidil in the perioperative neurosurgical setting.
Summary:
- Urapidil was administered to 31 patients during neurosurgical procedures.
- Dosing included an inductive phase (0.7-1 mg/kg) and a preoperative phase (0.6-0.8 mg/kg/h).
- Urapidil achieved a mean arterial pressure (MAP) reduction of approximately 25% without significant changes in heart rate or other monitored parameters.
Impact:
- Urapidil demonstrates potential as a safe and effective agent for managing blood pressure in neurosurgical patients.
- This study provides evidence for the perioperative use of urapidil in this specific patient population.
- Further research may explore long-term outcomes and comparisons with other antihypertensive agents.